Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Rolando Cimaz, Gabriella Maioli & Giulia Calabrese. (2020) Current and emerging biologics for the treatment of juvenile idiopathic arthritis. Expert Opinion on Biological Therapy 20:7, pages 725-740.
Read now
Read now
Shira Cohen & Pnina Fishman. (2019) Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy. Drug Design, Development and Therapy 13, pages 491-497.
Read now
Read now
C Diener & G Horneff. (2019) Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review. Expert Opinion on Drug Safety 18:8, pages 719-732.
Read now
Read now
Shinji Akioka. (2019) Interleukin-6 in juvenile idiopathic arthritis. Modern Rheumatology 29:2, pages 275-286.
Read now
Read now
Nami Okamoto, Shumpei Yokota, Syuji Takei, Yuka Okura, Tomohiro Kubota, Masaki Shimizu, Tomo Nozawa, Naomi Iwata, Hiroaki Umebayashi, Noriko Kinjo, Tomoko Kunishima, Junko Yasumura & Masaaki Mori. (2019) Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018. Modern Rheumatology 29:1, pages 41-59.
Read now
Read now
Tomohiro Kubota, Syuji Takei, Masaki Shimizu, Junko Yasumura, Yasuo Nakagishi, Toshitaka Kizawa, Masato Yashiro, Hiroyuki Wakiguchi, Yuichi Yamasaki & Yoshifumi Kawano. (2018) Early prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis: A multi-institutional study in Japan. Modern Rheumatology 28:5, pages 826-831.
Read now
Read now
Xiaoping Zhang, Ya-Chi Chen & Kimio Terao. (2017) Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis. Expert Review of Clinical Pharmacology 10:5, pages 471-482.
Read now
Read now
Sandra Helena Machado & Ricardo Machado Xavier. (2017) Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opinion on Drug Safety 16:4, pages 493-500.
Read now
Read now
Mikiya Fujieda, Kazushi Tsuruga, Tetsuya Sato, Hiroaki Kikuchi, Wataru Tamaki, Masayuki Ishihara, Masaki Yamamoto, Taku Oishi, Hiroshi Tanaka & Masanori Daibata. (2017) Monitoring of Epstein–Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab. Modern Rheumatology 27:1, pages 66-71.
Read now
Read now
Tomohiro Kubota, Hiroyuki Imanaka, Syuji Takei, Tsuyoshi Yamatou, Yasuhito Nerome, Yuuichi Yamasaki, Yukiko Nonaka, Harumi Akaike, Tomoko Takezaki & Yosihumi Kawano. (2016) Disease activity score in 28 joints at 3 months after the initiation of biologic agent can be a predictive target for switching to the second biologic agent in patients with polyarticular juvenile idiopathic arthritis. Modern Rheumatology 26:3, pages 358-361.
Read now
Read now
Özgül Muştu Koryürek & Göknur Kalkan. (2016) A new alternative therapy in dermatology: tocilizumab. Cutaneous and Ocular Toxicology 35:2, pages 145-152.
Read now
Read now
Jessica L. Turnier & Hermine I. Brunner. (2016) Tocilizumab for treating juvenile idiopathic arthritis. Expert Opinion on Biological Therapy 16:4, pages 559-566.
Read now
Read now
Gerd Horneff. (2015) Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opinion on Drug Safety 14:7, pages 1111-1126.
Read now
Read now
Tomomi Tsuru, Kimio Terao, Miho Murakami, Takaji Matsutani, Midori Suzaki, Toshiaki Amamoto, Hitoshi Nakashima, Azusa Akiyama & Norihiro Nishimoto. (2014) Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Modern Rheumatology 24:3, pages 511-516.
Read now
Read now
Troels Herlin. (2012) Tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Review of Clinical Immunology 8:6, pages 517-525.
Read now
Read now
Articles from other publishers (27)
Lenita de Melo Lima, Rafaela Baroni Aurilio, Adriana Rodrigues Fonseca, Ana Alice Amaral Ibiapina Parente, Maria de Fátima Bazhuni Pombo Sant’Anna & Clemax Couto Sant’Anna. (2023) Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review. Revista Paulista de Pediatria 42.
Crossref
Crossref
Vildan Güngörer, Elif Çelikel, Zahide Ekici Tekin, Merve Cansu Polat, Nimet Öner, Tuba Kurt, Melike Mehveş Kaplan, Müge Sezer, Nilüfer Tekgöz, Cüneyt Karagöl, Serkan Coşkun & Banu Çelikel Acar. (2023) Biological Agent Switching in Patients With Juvenile Idiopathic Arthritis. JCR: Journal of Clinical Rheumatology Publish Ahead of Print.
Crossref
Crossref
Reyhaneh Sabourian, Seyedeh Zohreh Mirjalili & Nima Rezaei. 2022. Translational Autoimmunity. Translational Autoimmunity
205
242
.
Tiago Borges, Arsénio Barbosa & Sérgio Silva. 2022. Translational Autoimmunity. Translational Autoimmunity
83
114
.
Daniel D Reiff, Matthew L Stoll & Randy Q Cron. (2021) Precision medicine in juvenile idiopathic arthritis—has the time arrived?. The Lancet Rheumatology 3:11, pages e808-e817.
Crossref
Crossref
Ernest H. Choy, Fabrizio De Benedetti, Tsutomu Takeuchi, Misato Hashizume, Markus R. John & Tadamitsu Kishimoto. (2020) Translating IL-6 biology into effective treatments. Nature Reviews Rheumatology 16:6, pages 335-345.
Crossref
Crossref
Fatma Yazılıtaş, Semanur Özdel, Doğan Şimşek, Özlem Aydoğ, Evrim Kargın Çakıcı, Gökçe Gür Can, Tülin Güngör & Mehmet Bülbül. (2019) Tocilizumab for juvenile idiopathic arthritis: a single-center case series. Sao Paulo Medical Journal 137:6, pages 517-522.
Crossref
Crossref
Ryoki Hara, Hiroaki Umebayashi, Syuji Takei, Nami Okamoto, Naomi Iwata, Yuichi Yamasaki, Yasuo Nakagishi, Toshitaka Kizawa, Ichiro Kobayashi, Tomoyuki Imagawa, Noriko Kinjo, Norihito Amano, Yoko Takahashi, Masaaki Mori, Yasuhiko Itoh & Shumpei Yokota. (2019) Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study. Pediatric Rheumatology 17:1.
Crossref
Crossref
Martijn J H Doeleman, Erik M van Maarseveen & Joost F Swart. (2019) Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatology 58:10, pages 1839-1849.
Crossref
Crossref
Michihiro Yabe, Kei Ishibashi, Akifumi Onagi, Ryo Tanji, Ruriko Honda-Takinami, Tomoyuki Koguchi, Kanako Matsuoka, Seiji Hoshi, Junya Hata, Masao Kataoka, Soichiro Ogawa, Hiroyuki Hiraki, Nobuhiro Haga & Yoshiyuki Kojima. (2018) Suppression of SOCS3 enhances TRAIL-induced cell growth inhibition through the upregulation of DR4 expression in renal cell carcinoma cells. Oncotarget 9:60, pages 31697-31708.
Crossref
Crossref
Violetta Opoka-Winiarska, Zbigniew Żuber, Ekaterina Alexeeva, Vyacheslav Chasnyk, Irina Nikishina, Grażyna Dębowska & Elżbieta Smolewska. (2018) Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial. Clinical Rheumatology 37:7, pages 1807-1816.
Crossref
Crossref
Andrea Rubbert-Roth, Daniel E. Furst, Jan Michael Nebesky, Angela Jin & Erhan Berber. (2018) A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases. Rheumatology and Therapy 5:1, pages 21-42.
Crossref
Crossref
Masaaki Mori, Masao Nakagawa, Nao Tsuchida, Kou Kawada, Junko Sato, Michiyo Sakiyama, Shinya Hirano, Katsuaki Sato & Hidefumi Nakamura. (2018) Proposal for the development of biologics in pediatric rheumatology. Pediatrics International 60:2, pages 108-114.
Crossref
Crossref
Shigeomi TAKEDA, Masahiko KOIKE, Naoki IWATA, Mitsuro KANDA, Michitaka FUJIWARA & Yasuhiro KODERA. (2018) A Case of Esophageal Cancer Occurred in a Patient with Multicentric Castleman's Disease Treated by Using Tocilizumab—Report of a Case—トシリズマブ投与中のCastleman病患者に発生した食道癌の1例. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 79:5, pages 995-999.
Crossref
Crossref
Rolando Cimaz, Achille Marino & Alberto Martini. (2017) How I treat juvenile idiopathic arthritis: A state of the art review. Autoimmunity Reviews 16:10, pages 1008-1015.
Crossref
Crossref
Kei Ishibashi, Tobias Haber, Ines Breuksch, Susanne Gebhard, Takashi Sugino, Hitoshi Kubo, Junya Hata, Tomoyuki Koguchi, Michihiro Yabe, Masao Kataoka, Soichiro Ogawa, Hiroyuki Hiraki, Tomohiko Yanagida, Nobuhiro Haga, Joachim W. Thüroff, Dirk Prawitt, Walburgis Brenner & Yoshiyuki Kojima. (2017) Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. Oncotarget 8:33, pages 55230-55245.
Crossref
Crossref
Darong Kim, Hee Yeon Won, Eun Sook Hwang, Young-Kook Kim & Hea-Young Park Choo. (2017) Synthesis of benzoxazole derivatives as interleukin-6 antagonists. Bioorganic & Medicinal Chemistry 25:12, pages 3127-3134.
Crossref
Crossref
Toshio Tanaka & Masashi Narazaki. (2017) Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish. Journal of Scleroderma and Related Disorders 2:2_suppl, pages S20-S28.
Crossref
Crossref
Ya-Qun Zhou, Zheng Liu, Zhi-Heng Liu, Shu-Ping Chen, Man Li, Allahverdi Shahveranov, Da-Wei Ye & Yu-Ke Tian. (2016) Interleukin-6: an emerging regulator of pathological pain. Journal of Neuroinflammation 13:1.
Crossref
Crossref
Gabriella Giancane, Alessandro Consolaro, Stefano Lanni, Sergio Davì, Benedetta Schiappapietra & Angelo Ravelli. (2016) Juvenile Idiopathic Arthritis: Diagnosis and Treatment. Rheumatology and Therapy 3:2, pages 187-207.
Crossref
Crossref
Mikhail M Kostik, Margarita F Dubko, Vera V Masalova, Ludmila S Snegireva, Tatyana L Kornishina, Irina A Chikova, Eugenia A Isupova, Ekaterina M Kuchinskaya, Natalia I Glebova, Natalia V Buchinskaya, Olga V Kalashnikova & Vyacheslav G Chasnyk. (2015) Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis. Pediatric Rheumatology 13:1.
Crossref
Crossref
Yusuke Tozawa, Shouji Fujita, Shuji Abe, Koichi Kitamura & Ichiro Kobayashi. (2015) Radiological improvement by tocilizumab in polyarticular juvenile idiopathic arthritis. Pediatrics International 57:2, pages 307-310.
Crossref
Crossref
C. Le Stradic, C. Galeotti & I. Koné-Paut. (2014) Traitement par tocilizumab : expérience d’un centre de rhumatologie pédiatrique. Archives de Pédiatrie 21:12, pages 1299-1304.
Crossref
Crossref
Parvin Ataie-Kachoie, Mohammad H Pourgholami, Des R Richardson & David L Morris. (2014) Gene of the month: Interleukin 6 (IL-6). Journal of Clinical Pathology 67:11, pages 932-937.
Crossref
Crossref
Ruth Davies & Ernest Choy. (2014) Clinical experience of IL-6 blockade in rheumatic diseases—Implications on IL-6 biology and disease pathogenesis. Seminars in Immunology 26:1, pages 97-104.
Crossref
Crossref
Nora Honke, Kim Ohl, Anastasia Wiener, Jeff Bierwagen, Joachim Peitz, Stefano Di Fiore, Rainer Fischer, Norbert Wagner, Stefan Wüller & Klaus Tenbrock. (2014) The p38-Mediated Rapid Down-Regulation of Cell Surface gp130 Expression Impairs Interleukin-6 Signaling in the Synovial Fluid of Juvenile Idiopathic Arthritis Patients. Arthritis & Rheumatology 66:2, pages 470-478.
Crossref
Crossref
Shumpei Yokota, Toshio Tanaka & Tadamitsu Kishimoto. (2012) Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Therapeutic Advances in Musculoskeletal Disease 4:6, pages 387-397.
Crossref
Crossref